Abstract | BACKGROUND: METHODS: The authors investigated this issue in a cohort of 17,064 women who were diagnosed with hormone receptor-positive breast cancer in an integrated group practice health plan. Information on demographics, comorbidities, and the receipt of adjuvant endocrine therapy was available from electronic medical records and pharmacy records, respectively. Endometrial cancer information was obtained from the health plan's Surveillance, Epidemiology, and End Results-affiliated tumor registry, and rates were compared across endocrine therapy groups ( aromatase inhibitor, n = 5303; tamoxifen, n = 5155; switchers: both [n = 3787] or none [n = 2819]) using multivariable adjusted Cox proportional-hazards models. RESULTS:
Endometrial cancer incidence was a statistically significant 48% lower in the aromatase inhibitor group versus the tamoxifen group (hazard ratio, 0.52; 95% confidence interval, 0.31-0.87; P = .01). Endometrial cancer incidence was 29% lower in the aromatase inhibitor group versus the no endocrine therapy group (hazard ratio, 0.71; 95% confidence interval, 0.37-1.35; P = .30) and 33% lower in the aromatase inhibitor group versus the tamoxifen group (hazard ratio, 0.67; 95% confidence interval, 0.42-1.06; P = .08), but neither difference was statistically significant. Associations were stronger among those with good drug adherence. CONCLUSIONS:
|
Authors | Rowan T Chlebowski, Joanne E Schottinger, Jiaxiao Shi, Joanie Chung, Reina Haque |
Journal | Cancer
(Cancer)
Vol. 121
Issue 13
Pg. 2147-55
(Jul 01 2015)
ISSN: 1097-0142 [Electronic] United States |
PMID | 25757699
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Copyright | © 2015 American Cancer Society. |
Chemical References |
- Antineoplastic Agents, Hormonal
- Aromatase Inhibitors
- Tamoxifen
|
Topics |
- Aged
- Aged, 80 and over
- Antineoplastic Agents, Hormonal
(administration & dosage)
- Aromatase Inhibitors
(administration & dosage)
- Breast Neoplasms
(drug therapy, pathology)
- California
(epidemiology)
- Cohort Studies
- Endometrial Neoplasms
(epidemiology, prevention & control)
- Female
- Humans
- Incidence
- Middle Aged
- Survivors
(statistics & numerical data)
- Tamoxifen
(administration & dosage)
|